Progressive Familial Intrahepatic Cholestasis Type 2 Treatment - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511241152

Publication Date:

November 11, 2024

Pages:

100

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Progressive familial intrahepatic cholestasis (PFIC) type 2 is a rare genetic disorder that has no curative medication. Key players in the market only provide symptomatic treatment drugs.
The global market for Progressive Familial Intrahepatic Cholestasis Type 2 Treatment was estimated to be worth US$ 236 million in 2023 and is forecast to a readjusted size of US$ 340 million by 2030 with a CAGR of 5.4% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Progressive Familial Intrahepatic Cholestasis Type 2 Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment by region & country, by Type, and by Application.
The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Progressive Familial Intrahepatic Cholestasis Type 2 Treatment.
麻豆原创 Segmentation
By Company
Teva
AbbVie
Glenmark Pharmaceuticals
Par Pharmaceuticals
Mylan
Sanofi
Novartis
Akorn
Albireo Pharma
Mirum Pharmaceuticals
Segment by Type:
Ursodeoxycholic Acid
Cholestyramine
Rifampicin
Late Stage Pipeline Drugs
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Introduction
1.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size Forecast
1.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Trends & Drivers
1.3.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Industry Trends
1.3.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Drivers & Opportunity
1.3.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Challenges
1.3.4 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Players Revenue Ranking (2023)
2.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue by Company (2019-2024)
2.3 Key Companies Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment
2.6 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Competitive Analysis
2.6.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Ursodeoxycholic Acid
3.1.2 Cholestyramine
3.1.3 Rifampicin
3.1.4 Late Stage Pipeline Drugs
3.1.5 Others
3.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Type
3.2.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital Pharmacies
4.1.2 Retail Pharmacies
4.1.3 Online Pharmacies
4.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Application
4.2.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Region
5.1.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Region (2019-2024)
5.1.3 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Region (2025-2030)
5.1.4 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value, 2019-2030
5.2.2 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value, 2019-2030
5.3.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value, 2019-2030
5.5.2 South America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value
6.3 United States
6.3.1 United States Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value, 2019-2030
6.3.2 United States Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value, 2019-2030
6.4.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value, 2019-2030
6.5.2 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value, 2019-2030
6.6.2 Japan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value, 2019-2030
6.7.2 South Korea Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value, 2019-2030
6.9.2 India Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Teva
7.1.1 Teva Profile
7.1.2 Teva Main Business
7.1.3 Teva Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
7.1.4 Teva Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Teva Recent Developments
7.2 AbbVie
7.2.1 AbbVie Profile
7.2.2 AbbVie Main Business
7.2.3 AbbVie Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
7.2.4 AbbVie Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 AbbVie Recent Developments
7.3 Glenmark Pharmaceuticals
7.3.1 Glenmark Pharmaceuticals Profile
7.3.2 Glenmark Pharmaceuticals Main Business
7.3.3 Glenmark Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
7.3.4 Glenmark Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Par Pharmaceuticals Recent Developments
7.4 Par Pharmaceuticals
7.4.1 Par Pharmaceuticals Profile
7.4.2 Par Pharmaceuticals Main Business
7.4.3 Par Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
7.4.4 Par Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Par Pharmaceuticals Recent Developments
7.5 Mylan
7.5.1 Mylan Profile
7.5.2 Mylan Main Business
7.5.3 Mylan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
7.5.4 Mylan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Mylan Recent Developments
7.6 Sanofi
7.6.1 Sanofi Profile
7.6.2 Sanofi Main Business
7.6.3 Sanofi Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
7.6.4 Sanofi Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Sanofi Recent Developments
7.7 Novartis
7.7.1 Novartis Profile
7.7.2 Novartis Main Business
7.7.3 Novartis Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
7.7.4 Novartis Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 Novartis Recent Developments
7.8 Akorn
7.8.1 Akorn Profile
7.8.2 Akorn Main Business
7.8.3 Akorn Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
7.8.4 Akorn Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 Akorn Recent Developments
7.9 Albireo Pharma
7.9.1 Albireo Pharma Profile
7.9.2 Albireo Pharma Main Business
7.9.3 Albireo Pharma Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
7.9.4 Albireo Pharma Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 Albireo Pharma Recent Developments
7.10 Mirum Pharmaceuticals
7.10.1 Mirum Pharmaceuticals Profile
7.10.2 Mirum Pharmaceuticals Main Business
7.10.3 Mirum Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Products, Services and Solutions
7.10.4 Mirum Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (US$ Million) & (2019-2024)
7.10.5 Mirum Pharmaceuticals Recent Developments
8 Industry Chain Analysis
8.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Industrial Chain
8.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Teva
AbbVie
Glenmark Pharmaceuticals
Par Pharmaceuticals
Mylan
Sanofi
Novartis
Akorn
Albireo Pharma
Mirum Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.